Lacosamida Intas (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. This stabilises the neuronal membrane, limits repetitive firing, and lowers hyper‑excitability that contributes to seizure generation, providing anticonvulsant effects.

The dosage of Lacosamida Intas is individualized by the prescribing clinician based on the patient’s age, renal function, and therapeutic response. The prescriber determines the appropriate starting dose and titration schedule.

Safety data for lacosamide during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women.

To request Lacosamida Intas, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide is a sodium‑channel blocker that selectively enhances slow inactivation, differing from many older agents that affect fast inactivation. This mechanism may offer better tolerability for some patients and can be used as monotherapy or adjunctive therapy, providing an alternative to drugs such as carbamazepine or levetiracetam.

Lacosamida Intas should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Lacosamida Intas is taken orally, usually as a tablet, with or without food. The exact administration schedule, including timing and whether it is taken once or twice daily, is determined by the prescribing physician.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, potential suicidal thoughts or behavior, severe skin reactions like Stevens‑Johnson syndrome, and rare blood disorders. Patients should be monitored regularly for these events, especially during dose adjustments.

Lacosamida Intas is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is also advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking medications that may cause dangerous interactions.